DE2308240C3 - Oral oder parenteral verabreichbares antihypertensives Mittel - Google Patents

Oral oder parenteral verabreichbares antihypertensives Mittel

Info

Publication number
DE2308240C3
DE2308240C3 DE2308240A DE2308240A DE2308240C3 DE 2308240 C3 DE2308240 C3 DE 2308240C3 DE 2308240 A DE2308240 A DE 2308240A DE 2308240 A DE2308240 A DE 2308240A DE 2308240 C3 DE2308240 C3 DE 2308240C3
Authority
DE
Germany
Prior art keywords
hhap
dadc
hydrazino
day
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2308240A
Other languages
German (de)
English (en)
Other versions
DE2308240A1 (de
DE2308240B2 (de
Inventor
Emiliana Baldoli
Giuseppe Bianchi
Anna Maria Caravaggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruppo Lepetit SpA
Original Assignee
Gruppo Lepetit SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruppo Lepetit SpA filed Critical Gruppo Lepetit SpA
Publication of DE2308240A1 publication Critical patent/DE2308240A1/de
Publication of DE2308240B2 publication Critical patent/DE2308240B2/de
Application granted granted Critical
Publication of DE2308240C3 publication Critical patent/DE2308240C3/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE2308240A 1972-03-14 1973-02-20 Oral oder parenteral verabreichbares antihypertensives Mittel Expired DE2308240C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2179872 1972-03-14

Publications (3)

Publication Number Publication Date
DE2308240A1 DE2308240A1 (de) 1973-09-20
DE2308240B2 DE2308240B2 (de) 1977-11-24
DE2308240C3 true DE2308240C3 (de) 1978-07-13

Family

ID=11186980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2308240A Expired DE2308240C3 (de) 1972-03-14 1973-02-20 Oral oder parenteral verabreichbares antihypertensives Mittel

Country Status (12)

Country Link
JP (1) JPS4899314A (enExample)
AU (1) AU473956B2 (enExample)
BE (1) BE796759A (enExample)
CA (1) CA1018458A (enExample)
DE (1) DE2308240C3 (enExample)
FR (1) FR2181820B1 (enExample)
GB (1) GB1378102A (enExample)
IE (1) IE37171B1 (enExample)
IL (1) IL41405A (enExample)
NL (1) NL149704B (enExample)
PH (1) PH10526A (enExample)
ZA (1) ZA73478B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE3294T1 (de) * 1978-10-02 1983-05-15 Gruppo Lepetit S.P.A. 6-aminosubstituierte n-pyrrolyl-3-pyridazinamine, deren herstellung und sie enthaltende pharmazeutische antihypertensive zusammensetzungen.

Also Published As

Publication number Publication date
IL41405A (en) 1976-04-30
IL41405A0 (en) 1973-03-30
DE2308240A1 (de) 1973-09-20
ZA73478B (en) 1973-10-31
FR2181820A1 (enExample) 1973-12-07
AU473956B2 (en) 1976-07-08
BE796759A (fr) 1973-07-02
FR2181820B1 (enExample) 1975-10-31
PH10526A (en) 1977-05-30
NL149704B (nl) 1976-06-15
JPS4899314A (enExample) 1973-12-15
GB1378102A (en) 1974-12-18
NL7302391A (enExample) 1973-09-18
AU5327073A (en) 1974-09-19
CA1018458A (en) 1977-10-04
DE2308240B2 (de) 1977-11-24
IE37171L (en) 1973-09-14
IE37171B1 (en) 1977-05-25

Similar Documents

Publication Publication Date Title
EP0607775A2 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
DE1802394C2 (de) Arzneimittel mit antihypertensiver Wirkung, die [(2,6-Dichlorbenzyliden)-amino]-guanidin oder ein Säureadditionssalz davon enthalten
EP0038438B1 (de) Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel
EP0607776A2 (de) Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
DE3887591T2 (de) Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen.
DE2854316C2 (enExample)
DE2308240C3 (de) Oral oder parenteral verabreichbares antihypertensives Mittel
DE68907976T2 (de) Verwendung eines Thromboxan-A2-Rezeptorantagonist zur Herstellung eines Arzeneimittels zur Behandlung pulmonarer Hypertonie, die durch Protamin-induzierte Neutralisation von Heparin verursacht wird.
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
EP0132595B1 (de) Tokolytisches Mittel
DE3204732C2 (enExample)
EP0524512B1 (de) Antihypertensive Kombination
EP0005732B1 (de) Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris
DE3500756A1 (de) Verwendung von chinolonen zur behandlung der herzinsuffizienz
DE3213579C2 (enExample)
DE2952590A1 (de) Verwendung von pyridinderivaten zur behandlung von blutandrang verursachendem herzversagen
DE3141970A1 (de) Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen
DE2636328A1 (de) Arzneimittel
DE2823267C2 (enExample)
DD283931A5 (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen
CH661867A5 (de) Praeparat zur behandlung von hyperlipidaemie in der human- und veterinaermedizin.
DE2755018A1 (de) Mittel zur behandlung cardiovasculaerer stoerungen bei saeugetieren
EP0334164B1 (de) Antihypertensives Kombinationspräparat
DE2410181C3 (de) Arzneimittel zur oralen Lithium-Behandlung
DE3239714C2 (de) Verwendung von 5-Methyl-7-dietylamino-s-triazolo-(1,5-a)-pyrimidin zusammen mit einem }blichen pharmazeutisch annehmbaren Tr{ger zur Behandlung von chronischen okklusiven Lungenerkrankungen

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee